Presentation is loading. Please wait.

Presentation is loading. Please wait.

John Nkengasong, PhD Associate Director for Laboratory Sciences & Chief, International Laboratory Branch Division of Global HIV/AIDS CDC, Atlanta, Georgia.

Similar presentations


Presentation on theme: "John Nkengasong, PhD Associate Director for Laboratory Sciences & Chief, International Laboratory Branch Division of Global HIV/AIDS CDC, Atlanta, Georgia."— Presentation transcript:

1 John Nkengasong, PhD Associate Director for Laboratory Sciences & Chief, International Laboratory Branch Division of Global HIV/AIDS CDC, Atlanta, Georgia Technical and Operational Considerations for Scaling Up HIV Viral Load Testing Center for Global Health Division of Global HIV/AIDS

2

3 Phased Implementation of Viral Load Testing Phase I: Planning Policies and Leadership Harmonization Algorithm Mapping and Forecasting Assess Capacity Costing Specimen and Product Selection Equipment Procurement Phase II: Scale Up Phase In Human Resources Training and Supervision Quality Management System Phase III: Sustainability Partner Harmonization M&E Data Collection Operational Research

4 Policies and Leadership Harmonization Algorithm Mapping and Forecasting Assess Capacity Costing Specimen and Product Selection Equipment Procurement Phase I: Planning

5 Developing an Algorithm for Monitoring Viral Load Frequency of viral load testing Definition of viral failure Repeat testing with viral failure Specimen type Population-specific testing algorithms Projected number of people on ART

6 Framework for Developing a Sustainable Viral Load Network Key Elements for Viral Load Networks Impact on Patient Monitoring, Treatment Adherence, and Viral Load Suppression Equipment Information Management Systems Quality Management Systems M & E Technology Evaluation Policy & Strategic Planning and Coverage Specimen Referral Sustain Program Implementation

7 Performance Characteristics of DBS Viral Load Testing by Different Platforms [at 1000 Copies/mL] VIRAL LOAD ASSAY Sensitivity (mean %) Specificity (mean %) n Abbott Molecular: Abbott RealTime HIV-1 (manual, m24sp and m2000sp) assays with m2000rt platform Biocentric: Generic HIV Charge Virale bioMérieux: NucliSENS EasyQ ® HIV-1 v Roche Molecular Systems: COBAS ® AmpliPrep/Taqman ® HIV-1 Test, Version 2.0 [free virus elution protocol] Siemens VERSANT ® HIV-1 RNA 1.0 Assay (kPCR)

8 Advantage of Using Plasma or DBS for Viral Load Testing Plasma Specimens Gold standard to determine viral failure Requires stringent processing and storage conditions Accurate on all platforms DBS Specimens Easy preparation using whole blood Minimal transportation requirements; not considered biohazardous Not as time and temperature sensitive as whole blood or plasma

9 Technologies for Scaling Up Viral Load Networks Key Messages Options for viral load scale up Selection criteria Impact of point-of-care technologies Centralized platforms Dried blood spots Point of care

10 Phase II: Scale Up Phase In Human Resources Training and Supervision Quality Management System

11 Quality Management System for Viral Load Networks Proficiency testing and quality control Continual training and competence assessment Quality managers Data quality checks Monitoring and evaluation system

12 Phase III: Sustainability

13 Harmonization Among Partners Coordination among all stakeholders Harmonize existing capacity Streamlined efforts Joint targeted support

14 Concluding Remarks Leadership of Ministries of Health Systematic approach for implementing viral load networks (Phases I-III) Critical role of partnerships Developing a robust and sustainable HIV viral load testing network involves: A sustainable viral load network improves: patient outcome, treatment adherence, and viral load suppression.


Download ppt "John Nkengasong, PhD Associate Director for Laboratory Sciences & Chief, International Laboratory Branch Division of Global HIV/AIDS CDC, Atlanta, Georgia."

Similar presentations


Ads by Google